Creating value with biosimilars

Through our biosimilar development projects, Formycon creates not only highly effective, more affordable biologic drugs for patients but also long-term value for its investors. Biosimilars are a new class of medicines with a very promising future, and our product candidates are targeted at multi-billion-dollar markets.

Formycon AG share chart

Shareholder structure

  24,3% ATHOS KG
■   13,6% Wendeln & Cie. KG
9,0% Gedeon Richter
6,0% Active Ownership Corporations S.á.r.l
5,0% DSP Beteiligungsgesellschaft GmbH & Co. KG
5,9% Founders and Management
36,2% Free Float

Legal form

German stock corporation (Aktiengesellschaft)

Initial exchange listing

December 20, 2010





Exchange and market segment

Frankfurt Stock Exchange “Scale” Segment (Open Market)

Share type

Bearer shares without par value

Registered capital

EUR 17,656,902.00

Shares outstanding

17,656,902 bearer shares

Capital Market Partner

B. Metzler seel. Sohn & Co. Aktiengesellschaft

Wolfgang Steubing AG

Designated Sponsors

Oddo BHF Corporates & Markets AG
M.M. Warburg & Co.

as of December 2023



as of January 2024